Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Adipose tissue derived Mesenchymal Stem cells (ATMSC) will be injected in patients diagnosed with Knee osteoarthrosis
Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to specific inclusion and exclusion criteria. These patients will be injected with Adipose Tissue derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| adipose tissue mesenchymal stem cell | Experimental | Intra-articular adipose tissue derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of ATMSC in each dose |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Adipose tissue derived mesenchymal stem cell | Biological | Intra-articular adipose tissue derived mesenchymal stem cell injection. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of the safety and tolerability of the intra articular injection | patients will be monitored for any adverse events resulting from the intraarticular injection of ATMSC | Time Frame: 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of the efficacy of intra-articular injection of ATMSC | The efficacy of the intra-articular injection of ATMSC will be assessed by Magnetic Resonance Imaging (MRI). | 12 months |
Not provided
Inclusion Criteria:
Severe KOA stage III or IV by Laurance & Kellgren staging as judged by Posterioranterior (PA) Xray of the knee joint.
Willing to participate by signing the informed consent
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hanan Jafar, PhD | Contact | 00962798871087 | hanan.jafar@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Abdallah Awidi, MD | Cell Therapy Center | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cell Therapy Center | Recruiting | Amman | 11942 | Jordan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42049633 | Derived | Jafar H, Samara O, Shahin D, Daoud F, Al-Hattab D, Samara A, Al Lawama L, Hamdan M, Qubbaj H, Salah B, Awidi A. Intra-articular allogeneic adipose-derived mesenchymal stromal cell injections for stage III knee osteoarthritis: a double-blind placebo-controlled trial with 60-month follow-up. Stem Cells Transl Med. 2026 Apr 27;15(5):szag018. doi: 10.1093/stcltm/szag018. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020370 | Osteoarthritis, Knee |
| D010003 | Osteoarthritis |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided